{Reference Type}: Journal Article
{Title}: Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.
{Author}: Jabbari A;Dai Z;Xing L;Cerise JE;Ramot Y;Berkun Y;Sanchez GA;Goldbach-Mansky R;Christiano AM;Clynes R;Zlotogorski A;
{Journal}: EBioMedicine
{Volume}: 2
{Issue}: 4
{Year}: Apr 2015
{Factor}: 11.205
{DOI}: 10.1016/j.ebiom.2015.02.015
{Abstract}: <B>BACKGROUND: </B>Alopecia areata (AA) is an autoimmune disease resulting in hair loss with devastating psychosocial consequences. Despite its high prevalence, there are no FDA-approved treatments for AA. Prior studies have identified a prominent interferon signature in AA, which signals through JAK molecules.<BR><B>METHODS: </B>A patient with AA was enrolled in a clinical trial to examine the efficacy of baricitinib, a JAK1/2 inhibitor, to treat concomitant CANDLE syndrome. In vivo, preclinical studies were conducted using the C3H/HeJ AA mouse model to assess the mechanism of clinical improvement by baricitinib.<BR><B>RESULTS: </B>The patient exhibited a striking improvement of his AA on baricitinib over several months. In vivo studies using the C3H/HeJ mouse model demonstrated a strong correlation between resolution of the interferon signature and clinical improvement during baricitinib treatment.<BR><B>CONCLUSIONS: </B>Baricitinib may be an effective treatment for AA and warrants further investigation in clinical trials.